Related Experiment Video

Updated: May 9, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Celecoxib inhibits insulin-like growth factor 1 induced growth and invasion in non-small cell lung cancer

Chen-Hui Liu1, Hong-Guang Bao, Ya-Li Ge

  • 1Departments of Anesthesiology, Affiliated Nanjing Hospital of Nanjing Medical University, Nanjing 210006, P.R. China.

Oncology Letters
|July 9, 2013
PubMed

Insights

Celecoxib hinders non-small cell lung cancer (NSCLC) growth and invasion by impacting the insulin-like growth factor (IGF) axis. This study reveals potential new anticancer mechanisms for celecoxib in NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Celecoxib is recognized for its role in tumor prevention and treatment.
  • The precise molecular mechanisms underlying celecoxib's anticancer effects remain incompletely understood.
  • The insulin-like growth factor (IGF) axis is implicated in various cancers, including non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the impact of celecoxib on insulin-like growth factor 1 (IGF-1)-induced proliferation and invasion in NSCLC cells.
  • To elucidate the molecular pathways through which celecoxib exerts its effects on NSCLC.
  • To explore the modulation of the IGF axis as a potential mechanism for celecoxib's anticancer activity.

Main Methods:

  • A549 NSCLC cells were treated with IGF-1 in the presence or absence of varying concentrations of celecoxib.
  • Cell proliferation and invasion assays were performed to assess cellular responses.
  • Western blot analysis was used to examine the expression of phosphorylated type-1 IGF receptor (IGF-1R) and phosphorylated AKT (p-AKT).
  • Enzyme-linked immunosorbent assay (ELISA) was employed to measure IGF-binding protein-3 (IGFBP-3) levels.

Main Results:

  • Celecoxib demonstrated a dose-dependent inhibition of IGF-1-stimulated cell growth and invasion in A549 cells.
  • Celecoxib treatment led to a reduction in the expression of IGF-1R and IGFBP-3.
  • The phosphorylation of AKT (p-AKT) was decreased following celecoxib administration.
  • These findings indicate that celecoxib interferes with key components of the IGF signaling pathway.

Conclusions:

  • Modulating the IGF axis represents a potential novel mechanism for the anticancer effects of celecoxib in NSCLC.
  • Celecoxib's ability to inhibit IGF-1-induced growth and invasion highlights its therapeutic potential in NSCLC.
  • Further research into the IGF axis may uncover new therapeutic strategies involving celecoxib for NSCLC treatment.
Keywords:
celecoxibinsulin-like growth factor axisnon-small cell lung cancerp-AKT

More Related Videos

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...